Immunotherapy in acute myeloid leukemia

Immunotherapy

Volumn 6, Issue 1, 2014, Pages 95-106

  Arpinati, Mario ^a   Curti, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

acute myeloid leukemia; allogeneic AML; immune escape; immunotherapy; NK cells; vaccines

Indexed keywords

AZACITIDINE; CANCER VACCINE; CYTOTOXIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; LEUKEMIA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE VACCINE; PROTEINASE; PROTEINASE 1; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; APOPTOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CROSS PRESENTATION; CYTOKINE INDUCED KILLER CELL; DONOR LYMPHOCYTE INFUSION; EVENT FREE SURVIVAL; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; LEUKEMIA CELL; MAINTENANCE THERAPY; MALIGNANT TRANSFORMATION; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ESCAPE;

ANTIGENS, NEOPLASM; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; TUMOR ESCAPE;

EID: 84896524135     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.152     Document Type: Review

References (120)

1. Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89, 3323-3329 (1997).
2. Swann JB, Smyth MJ. Immune surveillance of tumors. J. Clin. Invest. 117, 1137-1146 (2007).
3. Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 118, 5084-5095 (2011).
4. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today 20, 469-473 (1999).
5. Frumento G, Rotondo R, Tonetti M et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459-468 (2002).
6. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24, 242-248 (2003).
7. Munn DH, Sharma MD, Lee JR et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867-1870 (2002).
8. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103, 4619-4621 (2004).
9. Uyttenhove C, Pilotte L, Théate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269-1274 (2003).
10. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol. Med. 10, 15-18 (2004).
11. Kudo Y, Boyd CA, Spyropoulou I et al. Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta. J. Reprod. Immunol. 61, 87-98 (2004).
12. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998).
13. Heikkinen J, Mottonen M, Alanen A, Lassila O. Phenotypic characterization of regulatory T cells in the human decidua. Clin. Exp. Immunol. 136, 373-378 (2004).
14. Bozza S, Fallarino F, Pitzurra L et al. A crucial role for tryptophan catabolism at the host/Candida albicans interface. J. Immunol. 174, 2910-2918 (2005).
15. Munn DH, Sharma MD, Hou D et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280-290 (2004).
16. Curti A, Aluigi M, Pandolfi S et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 21, 353-355 (2007).
17. Curti A, Pandolfi S, Valzasina B et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 109, 2871-2877 (2007).
18. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715-727 (2006).
19. Anasetti C, Mulé JJ. To ablate or not to ablate? HSCs in the T cell driver's seat. J. Clin. Invest. 117, 306-310 (2007).
20. Wang F, Bade E, Kuniyoshi C et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 5, 2756-2765 (1999).
21. Gattinoni L, Finkelstein SE, Klebanoff CA et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907-912 (2005).
22. Dummer W, Niethammer AG, Baccala R et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110, 185-192 (2002).
23. Cho BK, Rao VP, Ge Q et al. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J. Exp. Med. 192(4), 549-556 (2000).
24. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323-5337 (2009).
25. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101(38), 13885-13890 (2004).
26. Mailänder V, Scheibenbogen C, Thiel E et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18, 165-166 (2004).
27. Keilholz U, Letsch A, Busse A et al. A clinical and immunologic Phase 2 trial of Wilms' tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113, 6541-6548 (2009).
28. Rezvani K, Young ASM, Mielke S et al. Leukemia-associated antigen specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111, 236-242 (2008).
29. Pinilla-Ibarz J, May RJ, Korontsvit T et al. Improved human T-cell responses against synthetic HLA0201 analog peptides derived from the WT1 oncoprotein. Leukemia 20, 2025-2033 (2006).
30. Asemissen A, Keilholz U, Tenzer S et al. Identification of a highly immunogenic HLAA 01-binding T cell epitope of WT1. Clin. Cancer Res. 12, 7476-7482 (2006).
31. van Tendeloo VF, van de Velde A, van Driessche A et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA 107(31), 13824-13829 (2010).
32. Curti A, Trabanelli S, Onofri C et al. Indoleamine 2,3-dioxygenase- expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica 95, 2022-2030 (2010).
33. Borrello IM, Levitsky HI, Stock W et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 114(9), 1736-1745 (2009).
34. Cui Y, Kelleher E, Straley E et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat. Med. 9, 952-958 (2003).
35. Lanier LL. NK cell receptors. Annu. Rev. Immunol. 16, 359-393 (1998).
36. Farad SS, Fehniger T, Ruggeri L et al. Natural killer cell receptors: new biology and insights into graft versus leukemia effect. Blood 100, 1935-1947 (2002).
37. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002).
38. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLAmismatched hematopoietic stem cell transplantation. Blood 94, 333-339 (1999).
39. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057 (2005).
40. Rubnitz JE, Inaba H, Ribeiro RC et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28, 955-959 (2010).
41. Curti A, Ruggeri L, D'Addio A et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118, 3273-3279 (2011).
42. Litzow MR, Tarima S, Perez WS et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 115, 1850-1857 (2010).
43. Parmar S, Fernandez-Vima M, de Lima M. Novel transplant strategies for generating graft-versus leukemia effect in acute myeloid leukemia. Curr. Opin. Hematol. 18, 98-104 (2011).
44. Barnes DWH, Corp MJ, Loutit JF et al. Treatment of murine leukaemia with x-rays and homologous bone marrow. Preliminary communication. Br. Med. J. 2, 626-627 (1956).
45. Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300, 1068-1073 (1979).
46. Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease - contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med. 304, 1529-1533 (1981).
47. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555-562 (1990).
48. Wagner JE, Thompson JS, Carter SL et al. Effect of graft-versus-host disease prophylaxis on 3year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): a multi-centre randomised Phase II-III trial. Lancet 366, 733-741 (2005).
49. Higano CS, Brixey M, Bryant EM et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogenic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 50, 175-177 (1990).
50. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 9, 123-127 (2002).
51. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86, 2041-2050 (1995).
52. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 41, 483-493 (2008).
53. Yegin ZA, Ozkurt ZN, Aki SZ et al. Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation. Transus. Apher. Sci. 42, 239-245 (2010).
54. Huang XJ, Liu DH, Liu KY et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLAmismatched/ haploidentical T-cell replete hematopoietic stem cell transplantation. Haematologica 92, 414-417 (2007).
55. Raiola AM, Van Lint MT, Valbonesi M et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant. 31, 687-693 (2003).
56. Levine JE, Braun T, Penza SL et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J. Clin. Oncol. 20(2), 405-412 (2002).
57. Warlick ED, DeFor T, Blazar BR et al. Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 18, 480-486 (2012).
58. Massenkeil G, Nagy M, Lawang M et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant. 31, 339-345 (2003).
59. Schmid C, Labopin M, Nagler A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J. Clin. Oncol. 25, 4938-4945 (2007).
60. Levine JE, Barrett AJ, Zhang MJ et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant. 42, 201-205 (2008).
61. Ferrara JL, Levine JE, Reddy P et al. Graft-versus-host disease. Lancet 373, 1550-1561 (2009).
62. Chakraverty R, Eom H, Sachs J et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-dependent graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 108, 2106-2113 (2006).
63. Cheng H, Tian J, Li Z et al. Th17 cells are critical for skin-specific pathological injury in acute graft-versus-host disease. Transplant. Proc. 44, 1412-1418 (2012).
64. Miklos DB, Kim HT, Miller KH et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft versus host disease and disease remission. Blood 105, 2973-2978 (2005).
65. Vago L, Perna SK, Zanussi M et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med. 361, 478-488 (2009).
66. Spierings E, Kim YH, Hendriks M et al. Multi-center analyses demonstrate significant clinical effects of minor histocompatibility antigens on GVHD and GVL after HLA matched related and unrelated hematopoietic stem-cell transplantation. Biol. Blood Marrow Transplant. 19(8), 1244-1253 (2013).
67. Mutis T, Verdijk R, Schrama E et al. Feasibility of immunotherapy of relapsed leukemia with ex-vivo generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 93, 2336-2341 (1999).
68. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 91, 2197-2207 (1998).
69. Bonnet D, Warren EH, Greenberg PD et al. CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc. Natl. Acad. Sci. USA 96, 8639-8644 (1999).
70. Norde WJ, Overes IM, Maas F et al. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood 113, 2312-2323 (2009).
71. Dermime S, Molldrem J, Parker KC. Human CD8+ T lymphocytes recognize the fusion region of BCR/ABL hybrid protein present in chronic myeloid leukemia. Blood 86(Suppl.), 593 (1995).
72. Gao L, Bellantuono I, Elsasser A et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95, 2198-2203 (2000).
73. Molldrem J, Lee PP, Wang C et al. A PR-1- human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59, 2675-2681 (1999).
74. Molldrem J, Lee PP, Wang C et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6, 1018-1023 (2000).
75. Shlomchick WD. Graft-versus-host disease. Nat. Rev. Immunol. 7, 340-352 (2007).
76. Wang X, Li H, Matte-Martone C et al. Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross presentation and the appearance of cross-presentation. Blood 118, 6426-6437 (2011).
77. Re F, Arpinati M, Testoni N et al. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. Exp. Hematol. 30, 126-134 (2002).
78. Matte CC, Liu J, Cornier J et al. Donor APCs are required for maximal GVHD but not for GVL. Nat. Med. 10, 987-992 (2004).
79. Chakraverty R, Sykes M. The role of antigen presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood 110, 9-17 (2007).
80. Velardi A. Natural killer cell alloreactivity 10 years later. Curr. Opin. Hematol. 19, 421-426 (2012).
81. Cooley S, Weisdorf D. Natural killer cells and tumor control. Curr. Opin. Hematol. 17, 514-521 (2010).
82. Hsu KC, Keever-Taylor CA, Wilton A et al. Improved outcome in HLAidentical sibling donor hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105, 4878-4884 (2005).
83. Giebel S, Locatelli F, Lamparelli T et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102, 814-819 (2003).
84. Cooley S, Trachtenberg E, Bergemann TL et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113, 726-732 (2009).
85. Cooley S, Weisdorf DJ, Guethlein LA et al. Donor selection for natural killer cell receptor genes leads to superior after unrelated transplantation for acute myelogenous leukemia. Blood 116, 2411-2419 (2010).
86. Stringaris K, Adams S, Uribe M et al. Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLAidentical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol. Blood Marrow Transplant. 16, 1257-1264 (2010).
87. Savani BN, Mielke S, Adams S et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLAidentical stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Leukemia 21, 2145-1252 (2007).
88. Orti G, Lowdell M, Fielding A et al. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation. Transplantation 88, 1312-1318 (2009).
89. Porter DL, Levine BL, Bunin N et al. A Phase I trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 107, 1325-1331 (2006).
90. Rosenberg SA, Restifo NP, Yang JC et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299-308 (2008).
91. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038-1044 (1995).
92. Warren EH, Fujii N, Akatsuka Y et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplant with T-cells specific for minor histocompatibility antigens. Blood 115, 3869-3878 (2010).
93. Jedema I, Meij P, Steeneveld E et al. Early detection of and rapid isolation of leukemia reactive donor T cells for adoptive transfer using the IFNgamma secretion assay. Clin. Cancer Res. 13, 636-643 (2007).
94. Guo Y, Niiya H, Azuma T et al. Direct recognition and lysis of leukemia cells by WT1-specific CD54+ T lymphocytes in an HLA class II-restricted manner. Blood 106, 1415-1418 (2005).
95. Amrolia PJ, Reid SD, Gao L et al. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemia activity. Blood 101, 1007-1014 (2003).
96. Ma Q, Wang C, Jones D et al. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 12, 1056-1062 (2010).
97. Eljaafari A, Farre A, Duperier K et al. Generation of helper and cytotoxic CD4+ T cell clones specific for the minor histocompatibility antigen H-Y, after in vitro priming of human T cells by HLAidentical monocyte-derived dendritic cells. Transplantation 71, 1449-1455 (2001).
98. Mutis T, Schrama E, Melief CJ et al. CD80transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. Blood 92, 1677-1684 (1998).
99. Chen W, Qin H, Reese VA et al. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein. J. Immunother. 21, 257-268 (1998).
100. Bonini C, Ferrari G, Verzeletti S et al. HSV- TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724 (1995).
101. Ciceri F, Bonini C, Stanghellini MT et al. Infusion of sucide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem cell transplantation for leukemia (the TK007 trial): a non-randomised Phase I-II study. Lancet Oncol. 10, 489-500 (2009).
102. Stauss HJ, Thomas S, Cesco-Gaspere M et al. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol. Dis. 40, 113-116 (2008).
103. Heemskerk MH, Hoogeboom M, Hagedoorn R et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J. Exp. Med. 199, 885-894 (2004).
104. Tsuji T, Yasukawa M, Matsuzaki J et al. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106, 470-476 (2005).
105. Xue SA, Gao L, Hart D et al. Elimination of human leukemia cells in NOD\SCID mice by WT1 TCR gene-transduced human T cells. Blood 106, 3062-3067 (2005).
106. Bendle GM, Linnemann C, Hooijkass AI et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16, 565-570 (2010).
107. Provasi E, Genovese P, Lombardo A et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807-815 (2012).
108. Brentjens RJ, Curran KJ. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology 2012, 143-151 (2012).
109. Grupp SA, Kalos M, Barre D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
110. Dutour A, Marin V, Pizzitola I et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBC-CTL against CD33 acute myeloid leukemia. Adv. Hematol. 2012, 683065 (2012).
111. Champlin R, Fernandez-Vina M, Rondon G et al. Alloreactive NK cells to augment antileukemia cytotoxicity with allogeneic stem cell transplantation for AML/MDS: a Phase I study. Blood (ASH Annual Meeting Abstracts) 116 (2010) (Abstract 489).
112. Introna M, Franceschetti M, Ciocca A et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant. 38, 621-627 (2006).
113. Introna M, Pievani A, Borleri G et al. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol. Blood Marrow Transplant. 16, 1603-1607 (2010).
114. Borrello I, Sotomayor EM, Rattis FM et al. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95, 3011-3019 (2000).
115. Hashii Y, Sato-Miyashita E, Matsumura R et al. WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission. Leukemia 26, 530-532 (2012).
116. Maeda T, Hosen N, Fukushima K et al. Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine. Blood Cancer J. 3, e130 (2013).
117. Schlegel P, Teltschik HM, Pfeiffer M et al. Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children. Best Pract. Res. Clin. Haematol. 24, 443-452 (2011).
118. Posthuma EF, Marijt EW, Barge RM et al. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol. Blood Marrow Trans. 10, 204-212 (2004).
119. De Lima M, Giralt S, Thall PF et al. Maintenance therapy with low dose azacytidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome. Cancer 116, 5420-5431 (2010).
120. Goodyear O, Agathanggelou A, Novitzky- Basso I et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116, 1908-1918 (2010).